Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc.
Your view on VICP
Overview
What the company does, where it operates, and who runs it.
About Vicapsys Life Sciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Federico Pier
- Headquarters
- 1735 Buford Highway, Cumming, GA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Federico Pier
- Headquarters
- 1735 Buford Highway, Cumming, GA, US
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field.
The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vicapsys Life Sciences, Inc., and the rating behind it. VICP last traded at $1.50; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vicapsys Life Sciences, Inc.. Starting points for Vicapsys Life Sciences, Inc.: EPS -$0.0081, beta -4.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vicapsys Life Sciences, Inc.. Vicapsys Life Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vicapsys Life Sciences, Inc.. Trailing twelve-month EPS for Vicapsys Life Sciences, Inc. stands at -$0.0081. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vicapsys Life Sciences, Inc.. Vicapsys Life Sciences, Inc. has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vicapsys Life Sciences, Inc. valued side by side against its closest peers. Vicapsys Life Sciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vicapsys Life Sciences, Inc., and how their positions are changing. At a $48.6M market value, institutional positions materially move Vicapsys Life Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vicapsys Life Sciences, Inc. executives and directors. Shares of Vicapsys Life Sciences, Inc. have traded between $1.00 and $2.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vicapsys Life Sciences, Inc.. Vicapsys Life Sciences, Inc. is a $48.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vicapsys Life Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vicapsys Life Sciences, Inc.. Coverage tracks Vicapsys Life Sciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.